Desmethylselegiline
| Clinical data | |
|---|---|
| Other names | DMS; N-Desmethylselegiline; Norselegiline; L-Desmethyldeprenyl; L-DD; R-(–)-N-Desmethyldeprenyl; L-Nordeprenyl; N-Propargyl-L-amphetamine |
| Routes of administration | By mouth |
| Drug class | Monoamine oxidase inhibitor; Catecholaminergic activity enhancer; Norepinephrine–dopamine releasing agent |
| Pharmacokinetic data | |
| Metabolites | • Levoamphetamine |
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C12H15N |
| Molar mass | 173.259 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Desmethylselegiline (DMS), also known as norselegiline or as N-propargyl-L-amphetamine, is an active metabolite of selegiline, a medication used in the treatment of Parkinson's disease and depression.
Like selegiline, DMS is a monoamine oxidase inhibitor (MAOI); specifically, it is a selective and irreversible inhibitor of monoamine oxidase B (MAO-B). In addition, it is a catecholaminergic activity enhancer (CAE) similarly to selegiline. The drug also produces levoamphetamine as an active metabolite, which is a norepinephrine–dopamine releasing agent with sympathomimetic and psychostimulant effects.
DMS has been studied much less extensively than selegiline and has not been developed or approved for medical use.